Structural determinants of ligand binding to the mineralocorticoid receptor

Molecular and Cellular Endocrinology

Volumn 350, Issue 2, 2012, Pages 187-195

  Huyet, Jessica ^a,b,c   Pinon, Grégory Maurice ^a,b   Fay, Michel Raymond ^a,b   Rafestin Oblin, Marie Edith ^a,b   Fagart, Jérôme ^a,b,d  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d INSERM   (France)

Author keywords

Activation mechanism; Aldosterone; Antagonist; Mineralocorticoid receptor; Spirolactone; X ray crystal structure

Indexed keywords

7ALPHA PROPYLSPIRONOLACTONE; ALDOSTERONE; BR 4628; DIHYDROPYRIDINE DERIVATIVE; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PROTEIN P23; PROTEIN P70; PYRAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HYPERTENSION; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; WILD TYPE;

ALDOSTERONE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, MINERALOCORTICOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84856326788     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.07.035     Document Type: Review

References (70)

1. Arhancet G.B., Woodard S.S., Iyanar K., Case B.L., Woerndle R., Dietz J.D., Garland D.J., Collins J.T., Payne M.A., Blinn J.R., Pomposiello S.I., Hu X., Heron M.I., Huang H.C., Lee L.F. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists. J. Med. Chem. 2010, 53:5970-5978.
2. Auzou G., Fagart J., Souque A., Hellal-Levy C., Wurtz J.M., Moras D., Rafestin-Oblin M.E. A single amino acid mutation of ala-773 in the mineralocorticoid receptor confers agonist properties to 11beta-substituted spirolactones. Mol. Pharmacol. 2000, 58:684-691.
3. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., Consler T.G., Parks D.J., Stewart E.L., Willson T.M., Lambert M.H., Moore J.T., Pearce K.H., Xu H.E. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002, 110:93-105.
4. Bledsoe R.K., Madauss K.P., Holt J.A., Apolito C.J., Lambert M.H., Pearce K.H., Stanley T.B., Stewart E.L., Trump R.P., Willson T.M., Williams S.P. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J. Biol. Chem. 2005, 280:31283-31293.
5. Bocchi B., Fagart J., Cluzeaud F., Fay M., Rafestin-Oblin M.E., Farman N. Glucocorticoid metabolism by 11-beta hydroxysteroid dehydrogenase type 2 modulates human mineralocorticoid receptor transactivation activity. J. Steroid Biochem. Mol. Biol. 2003, 84:239-244.
6. Bonvalet J.P. Regulation of sodium transport by steroid hormones. Kidney Int. Suppl. 1998, 65:S49-56.
7. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 1995, 375:377-382.
8. Caamano C.A., Morano M.I., Patel P.D., Watson S.J., Akil H. A bacterially expressed mineralocorticoid receptor is associated in vitro with the 90-kilodalton heat shock protein and shows typical hormone- and DNA-binding characteristics. Biochemistry 1993, 32:8589-8595.
9. Corvol P., Mahoudeau J.A., Valcke J.C., Menard J., Bricaire H. Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action. Nouv. Presse Med. 1976, 5:691-694.
10. Couette B., Fagart J., Jalaguier S., Lombes M., Souque A., Rafestin-Oblin M.E. Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. Biochem. J. 1996, 315:421-427.
11. Couette B., Jalaguier S., Hellal-Levy C., Lupo B., Fagart J., Auzou G., Rafestin-Oblin M.E. Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor. Mol. Endocrinol. 1998, 12:855-863.
12. De Gasparo M., Joss U., Ramjoue H.P., Whitebread S.E., Haenni H., Schenkel L., Kraehenbuelh C., Biollaz M., Grob J., Schmidlin J., Wieland P., Wehrli H.U. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Therap. 1986, 240:650-656.
13. Dietz J.D., Du S., Bolten C.W., Payne M.A., Xia C., Blinn J.R., Funder J.W., Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008, 51:742-748.
14. Fagart J., Wurtz J.M., Souque A., Hellal-Levy C., Moras D., Rafestin-Oblin M.E. Antagonism in the human mineralocorticoid receptor. EMBO J. 1998, 17:3317-3325.
15. Fagart J., Seguin C., Pinon G.M., Rafestin-Oblin M.E. The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. Mol. Pharmacol. 2005, 67:1714-1722.
16. Fagart J., Huyet J., Pinon G.M., Rochel M., Mayer C., Rafestin-Oblin M.E. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat. Struct. Mol. Biol. 2005, 12:554-555.
17. Fagart J., Hillisch A., Huyet J., Barfacker L., Fay M., Pleiss U., Pook E., Schafer S., Rafestin-Oblin M.E., Kolkhof P. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J. Biol. Chem. 2010, 285:29932-29940.
18. Fuller P.J., Young M.J. Mechanisms of mineralocorticoid action. Hypertension 2005, 46:1227-1235.
19. Fuse H., Kitagawa H., Kato S. Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). Mol. Endocrinol. 2000, 14:889-899.
20. Galigniana M.D., Erlejman A.G., Monte M., Gomez-Sanchez C., Piwien-Pilipuk G. The hsp90-FKBP52 complex links the mineralocorticoid receptor to motor proteins and persists bound to the receptor in early nuclear events. Mol. Cell. Biol. 2010, 30:1285-1298.
21. Garthwaite S.M., McMahon E.G. The evolution of aldosterone antagonists. Mol. Cell. Endocrinol. 2004, 217:27-31.
22. Geller D.S., Farhi A., Pinkerton N., Fradley M., Moritz M., Spitzer A., Meinke G., Tsai F.T., Sigler P.B., Lifton R.P. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289:119-123.
23. Hassell A.M., An G., Bledsoe R.K., Bynum J.M., Carter H.L., Deng S.J., Gampe R.T., Grisard T.E., Madauss K.P., Nolte R.T., Rocque W.J., Wang L., Weaver K.L., Williams S.P., Wisely G.B., Xu R., Shewchuk L.M. Crystallization of protein-ligand complexes. Acta Crystallogr., D Biol. Crystallogr. 2007, 63:72-79.
24. Heery D.M., Kalkhoven E., Hoare S., Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 387:733-736.
25. Hellal-Levy C., Couette B., Fagart J., Souque A., Gomez-Sanchez C., Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett. 1999, 464:9-13.
26. Hellal-Levy C., Fagart J., Souque A., Rafestin-Oblin M.E. Mechanistic aspects of mineralocorticoid receptor activation. Kidney Int. 2000, 57:1250-1255.
27. Hellal-Levy C., Fagart J., Souque A., Wurtz J.M., Moras D., Rafestin-Oblin M.E. Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor. Mol. Endocrinol. 2000, 14:1210-1221.
28. Horisberger J.D., Rossier B.C. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 1992, 19:221-227.
29. Hultman M.L., Krasnoperova N.V., Li S., Du S., Xia C., Dietz J.D., Lala D.S., Welsch D.J., Hu X. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol. Endocrinol. 2005, 19:1460-1473.
30. Huyet J., Pinon G.M., Fay M.R., Fagart J., Rafestin-Oblin M.E. Structural basis of spirolactone recognition by the mineralocorticoid receptor. Mol. Pharmacol. 2007, 72:563-571.
31. Jalaguier S., Mesnier D., Lager J.L., Auzou G. Putative steroid binding domain of the human mineralocorticoid receptor, expressed in E. coli in the presence of heat shock proteins shows typical native receptor characteristics. J. Steroid Biochem. Mol. Biol. 1996, 57:43-50.
32. Kitagawa H., Yanagisawa J., Fuse H., Ogawa S., Yogiashi Y., Okuno A., Nagasawa H., Nakajima T., Matsumoto T., Kato S. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol. Cell. Biol. 2002, 22:3698-3706.
33. Kosaka H., Hirayama K., Yoda N., Sasaki K., Kitayama T., Kusaka H., Matsubara M. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur. J. Pharmacol. 2010, 635:49-55.
34. Landau R.L., Bergenstal D.M., Lugibihl K., Kascht M.E. The metabolic effects of progesterone in man. J. Clin. Endocrinol. Metab. 1955, 15:1194-1215.
35. Li Y., Suino K., Daugherty J., Xu H.E. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol. Cell 2005, 19:367-380.
36. Lombes M., Binart N., Delahaye F., Baulieu E.E., Rafestin-Oblin M.E. Differential intracellular localization of human mineralocorticosteroid receptor on binding of agonists and antagonists. Biochem. J. 1994, 302:191-197.
37. Losert W., Bittler D., Buse M., Casals-Stenzel J., Haberey M., Laurent H., Nickisch K., Schillinger E., Wiechert R. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists. Arzneimittelforschung 1986, 36:1583-1600.
38. Luisi B.F., Xu W.X., Otwinowski Z., Freedman L.P., Yamamoto K.R., Sigler P.B. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 1991, 352:497-505.
39. Meyers M.J., Arhancet G.B., Hockerman S.L., Chen X., Long S.A., Mahoney M.W., Rico J.R., Garland D.J., Blinn J.R., Collins J.T., Yang S., Huang H.C., McGee K.F., Wendling J.M., Dietz J.D., Payne M.A., Homer B.L., Heron M.I., Reitz D.B., Hu X. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J. Med. Chem. 2010, 53:5979-6002.
40. Moras D., Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 1998, 10:384-391.
41. Murai-Takeda A., Shibata H., Kurihara I., Kobayashi S., Yokota K., Suda N., Mitsuishi Y., Jo R., Kitagawa H., Kato S., Saruta T., Itoh H. NF-YC functions as a corepressor of agonist-bound mineralocorticoid receptor. J. Biol. Chem. 2010, 285:8084-8093.
42. Nedelec, L., Philibert, D., Torelli, V., 1986. Recent developments in the field of steroid antihormones. Third SCI-RSC Med. Chem. Sympo. 322-344.
43. Nemoto T., Ohara-Nemoto Y., Sato N., Ota M. Dual roles of 90-kDa heat shock protein in the function of the mineralocorticoid receptor. J. Biochem. (Tokyo) 1993, 113:769-775.
44. Ortlund E.A., Bridgham J.T., Redinbo M.R., Thornton J.W. Crystal structure of an ancient protein: evolution by conformational epistasis. Science 2007, 317:1544-1548.
45. Pinon G.M., Fagart J., Souque A., Auzou G., Vandewalle A., Rafestin-Oblin M.E. Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension. Mol. Cell. Endocrinol. 2004, 217:181-188.
46. Pippal J.B., Yao Y., Rogerson F.M., Fuller P.J. Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor. Mol. Endocrinol. 2009, 23:1360-1370.
47. Pippal J.B., Cheung C.M., Yao Y.Z., Brennan F.E., Fuller P.J. Characterization of the zebrafish (Danio rerio) mineralocorticoid receptor. Mol. Cell. Endocrinol. 2011, 332:58-66.
48. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N. Engl. J. Med. 1999, 341:709-717.
49. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003, 348:1309-1321.
50. Rafestin-Oblin M.E., Michaud A., Claire M., Corvol P. Dramatic protective effect of ligand against thermal degradation on mineraloand glucocorticoid receptors of rat kidney. J. Steroid. Biochem. 1977, 8:19-21.
51. Rafestin-Oblin M.E., Couette B., Radanyi C., Lombes M., Baulieu E.E. Mineralocorticosteroid receptor of the chick intestine. Oligomeric structure and transformation. J. Biol. Chem. 1989, 264:9304-9309.
52. Rafestin-Oblin M.E., Lombes M., Couette B., Baulieu E.E. Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp90 release from mineralocorticosteroid receptor. J. Steroid Biochem. Mol. Biol. 1992, 41:815-821.
53. + absorption in mammalian principal cortical collecting duct cells. Mol. Pharmacol. 2002, 62:1306-1313.
54. Rafestin-Oblin M.E., Souque A., Bocchi B., Pinon G., Fagart J., Vandewalle A. The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology 2003, 144:528-533.
55. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378:681-689.
56. Robertson N.M., Schulman G., Karnik S., Alnemri E., Litwack G. Demonstration of nuclear translocation of the mineralocorticoid receptor (MR) using an anti-MR antibody and confocal laser scanning microscopy. Mol. Endocrinol. 1993, 7:1226-1239.
57. Rogerson F.M., Dimopoulos N., Sluka P., Chu S., Curtis A.J., Fuller P.J. Structural determinants of aldosterone binding selectivity in the mineralocorticoid receptor. J. Biol. Chem. 1999, 274:36305-36311.
58. Rogerson F.M., Fuller P.J. Interdomain interactions in the mineralocorticoid receptor. Mol. Cell. Endocrinol. 2003, 200:45-55.
59. Rogerson F.M., Yao Y.Z., Elsass R.E., Dimopoulos N., Smith B.J., Fuller P.J. A critical region in the mineralocorticoid receptor for aldosterone binding and activation by cortisol: evidence for a common mechanism governing ligand binding specificity in steroid hormone receptors. Mol. Endocrinol. 2007, 21:817-828.
60. Rossi G., Boscaro M., Ronconi V., Funder J.W. Aldosterone as a cardiovascular risk factor. Trends Endocrinol. Metab. 2005, 16:104-107.
61. Rupprecht R., Reul J.M., van Steensel B., Spengler D., Söder M., Berning B., Holsboer F., Damm K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur. J. Pharmacol. 1993, 247:145-154.
62. Sartorato P., Cluzeaud F., Fagart J., Viengchareun S., Lombes M., Zennaro M.C. New naturally occurring missense mutations of the human mineralocorticoid receptor disclose important residues involved in dynamic interactions with deoxyribonucleic acid, intracellular trafficking, and ligand binding. Mol. Endocrinol. 2004, 18:2151-2165.
63. Smith D.F., Toft D.O. The intersection of steroid receptors with molecular chaperones: observations and questions. Mol. Endocrinol. 2008, 22:2229-2240.
64. Souque A., Fagart J., Couette B., Davioud E., Sobrio F., Marquet A., Rafestin-Oblin M.E. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Endocrinology 1995, 136:5651-5658.
65. Souque A., Fagart J., Couette B., Rafestin-Oblin M.E. Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor. J. Steroid Biochem. Mol. Biol. 1996, 57:315-321.
66. Tallec L.P., Kirsh O., Lecomte M.C., Viengchareun S., Zennaro M.C., Dejean A., Lombes M. Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol. Endocrinol. 2003, 17:2529-2542.
67. Wurtz J.M., Bourguet W., Renaud J.P., Vivat V., Chambon P., Moras D., Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 1996, 3:87-94.
68. Yang J., Young M.J. The mineralocorticoid receptor and its coregulators. J. Mol. Endocrinol. 2009, 43:53-64.
69. Yang J., Chang C.Y., Safi R., Morgan J., McDonnell D.P., Fuller P.J., Clyne C.D., Young M.J. Identification of ligand-selective peptide antagonists of the mineralocorticoid receptor using phage display. Mol. Endocrinol. 2011, 25:32-43.
70. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., Vincent J., Pocock S.J., Pitt B. EMPHASIS-HF Study Group, 2011. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011, 364:11-21.